Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
November 28, 2023 06:59 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the...
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
November 24, 2023 07:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the...
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
November 08, 2023 17:38 ET
|
Emergent BioSolutions
Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA(2) of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. ...
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
October 30, 2023 16:45 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the...
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
October 19, 2023 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
October 02, 2023 07:00 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective...
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
August 30, 2023 05:59 ET
|
Emergent BioSolutions
Emergent has officially shipped its over the counter, original prescription strength NARCAN® Naloxone HCl Nasal Spray 4 mg to leading mass, drug/pharmacy and grocery stores, as well as online...
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
August 08, 2023 16:31 ET
|
Emergent BioSolutions
Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56MUpdates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues ...
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
August 08, 2023 07:15 ET
|
Emergent BioSolutions
Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost savings over $100 million annually GAITHERSBURG, Md.,...
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
July 31, 2023 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development...